Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

NCT06717412

Status	RECRUITING
Phase	Not Applicable
Sponsor	Wang Yusheng
Enrollment	146 participants

Key Eligibility Criteria

Inclusion (5)

- Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age
- Bilateral type 1 ROP with one of the following retinal findings in each eye
- Zone I, stage 1+, 2+, 3+/- disease, or
- Zone II, stage 2+, 3+, disease, or
- A-ROP

Exclusion (10)

- Preterm infants with stage 4 or 5 ROP in one or both eyes
- Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy
- Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)
- Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer
- Have active ocular infection within 5 days before or on the day of first investigational treatment

... and 5 more (see full listing online)

Locations (3 total)

Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China
Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, China
Department of Ophthalmology, Xianyang Rainbow Hospital, Xianyang, Shaanxi, China